fosamprenavir has been researched along with ticlopidine in 1 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (ticlopidine) | Trials (ticlopidine) | Recent Studies (post-2010) (ticlopidine) |
---|---|---|---|---|---|
174 | 55 | 37 | 10,289 | 1,893 | 4,671 |
Protein | Taxonomy | fosamprenavir (IC50) | ticlopidine (IC50) |
---|---|---|---|
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.382 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 6.2928 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.304 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.175 | |
Cytochrome P450 2B6 | Homo sapiens (human) | 0.405 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.6678 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.426 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and ticlopidine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |